NCT04834778: A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least one measurable lesion
Exclusions: Patients with symptomatic, untreated, or actively progressing CNS metastases – see trial for details; Patients with a history of leptomeningeal disease

Comments are closed.

Up ↑